3.8 Article

Bloodstream infection in pediatric patients with febrile neutropenia induced by chemotherapy

Journal

HEMATOLOGY TRANSFUSION AND CELL THERAPY
Volume 45, Issue 2, Pages 170-175

Publisher

ELSEVIER
DOI: 10.1016/j.htct.2021.08.005

Keywords

Febrile neutropenia; Risk factor; Bacteremia; Cancer; Chemotherapy

Ask authors/readers for more resources

This study aimed to identify risk factors for documented infection in pediatric patients with febrile neutropenia and cancer. The study found that an CRP > 90mg/dl at the onset of a febrile episode, fever onset, and a positive first blood culture were independent risk factors for infection.
Introduction: Febrile neutropenia (FN) is a serious complication of cancer chemotherapy. The present study aimed to identify risk factors for documented infection in pediatric patients with FN and cancer.Methods: This prospective cohort study included patients under 18 years from 2016 to 2018. Infection was defined according to the Centers for Disease Control and Prevention criteria.Results: A total of 172 febrile neutropenic episodes were evaluated. From univariate analysis, the risk factors were: female gender; monocyte count < 100 cell/mm3, platelets < 50,000, C-reactive protein (CRP) > 90 mg/dl and hemoglobin < 7mg/dl at the onset of an episode; two or more episodes of FN, and; fever onset; positive blood culture at the fever onset. Independent risk factors according to the multivariate analysis were: CRP at the onset of a febrile episode > 90mg/dl, fever onset and first blood culture with a positive result. The lowest probability of infection was related to first episode and to platelets > 50,000 at the onset of fever.Conclusion: A CRP > 90 at the onset of a febrile episode, platelets < 50,000, second episode or more, first fever episode during hospitalization and positive first blood culture were found to be associated with a higher risk of infection and they could be useful for the establish-ment of risk scores for infection in neutropenic children.& COPY; 2021 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematolo-gia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available